WORK Medical announced Nasdaq's decision to delist its shares due to low closing bid prices, pending an appeal.
Quiver AI Summary
WORK Medical Technology Group LTD announced that it has received a delisting notice from Nasdaq due to its Class A ordinary shares closing at $0.10 or less for ten consecutive trading days as of October 8, 2025. The suspension of trading for its shares will begin on October 20, 2025, unless the company appeals the decision by October 16, 2025. WORK Medical plans to appeal and is exploring options, including a potential reverse share split, to regain compliance with Nasdaq's listing requirements. The company, based in China, specializes in developing and manufacturing medical devices, with a significant product portfolio and international sales.
Potential Positives
- The Company plans to appeal Nasdaq's delisting determination, which may provide an opportunity to regain compliance and avoid delisting.
- Work Medical has a diverse product portfolio with 21 products, highlighting its capability and presence in the medical devices market.
- The Company has successfully registered 17 products with the U.S. Food and Drug Administration, allowing for entry into the U.S. market, which enhances growth potential.
Potential Negatives
- The Company is facing delisting from the Nasdaq due to a prolonged low stock price, which raises concerns about its financial health and market confidence.
- The impending suspension of trading for the Company's Class A ordinary shares can negatively impact investor sentiment and may deter future investment.
- The Company must appeal the delisting decision, indicating a potential inability to meet Nasdaq's listing requirements, which could further harm its reputation and operational capabilities.
FAQ
What is the reason for WORK Medical's delisting from Nasdaq?
WORK Medical is being delisted due to a closing bid price of $0.10 or less for ten consecutive trading days.
When will WORK Medical's shares be suspended from trading?
Trading of WORK Medical’s Class A ordinary shares will be suspended on October 20, 2025.
Can WORK Medical appeal the Nasdaq delisting determination?
Yes, WORK Medical can request a hearing to appeal the delisting decision by October 16, 2025.
What measures is WORK Medical considering to regain Nasdaq compliance?
The Company may implement a reverse share split and explore other options to regain compliance with Nasdaq Listing Rules.
What products does WORK Medical offer?
WORK Medical develops and manufactures Class I and II medical devices, including masks and disposable medical consumables.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
Hangzhou, China, Oct. 14, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today announced that the Company received a determination letter, dated October 9, 2025 (the “Letter”), from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company of Nasdaq’s determination to delist the Company’s Class A ordinary shares from The Nasdaq Capital Market, because the Company’s Class A ordinary shares had a closing bid price of $0.10 or less for ten consecutive trading days ending October 8, 2025, which triggered a notice of delisting pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii).
Pursuant to the Letter, unless the Company requests an appeal, trading of the Company’s Class A ordinary shares will be suspended at the opening of business on October 20, 2025, and a Form 25-NSE will be filed with the U.S. Securities and Exchange Commission to remove the Company’s securities from listing and registration on Nasdaq.
The Company has the right to request a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal this determination, with such request due by October 16, 2025. A request for a hearing will stay the suspension of the Company’s securities pending the Panel’s decision. The Company plans to appeal the determination to the Panel on or before October 16, 2025.
The Company will consider all available options to regain compliance with the Nasdaq Listing Rules for continued listing on Nasdaq, including, if appropriate, implementing a reverse share split.
About WORK Medical Technology Group LTD
WORK Medical Technology Group LTD, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, is a supplier of medical devices that develops and manufactures Class I and II medical devices and sells Class I and II disposable medical devices through operating subsidiaries in China. The Company has a diverse product portfolio comprising 21 products, including customized and multifunctional masks and other medical consumables. All the products have been sold in 34 provincial-level administrative regions in China, with 15 of them sold in more than 30 countries worldwide. The Company has received a number of quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration allowing their products to enter the U.S. market. For more information, please visit the Company’s website: https://www.workmedtech.com/corporate .
Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any forward-looking statements in this press release are based on the Company’s current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results set forth in the Company’s annual report on Form 20-F and other documents filed by the Company with the U.S. Securities and Exchange Commission. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
For more information, please contact:
WORK Medical Technology Group LTD
Investor Relations Department
Email:
[email protected]
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email:
[email protected]